Top-News
Biotechnologie Schweden

Oncopeptides Ab Aktie

Aktie
WKN:  A2DLU2 ISIN:  SE0009414576 US-Symbol:  ONPPF
0,134 €
-0,0021 €
-1,54%
22:41:59 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
13,75 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-

Oncopeptides Ab News

29.07.22 - PR Newswire
Number of shares and votes in Oncopeptides
Number of shares and votes in Oncopeptides PR Newswire
29.07.22 - PR Newswire
Number of shares and votes in Oncopeptides
Number of shares and votes in Oncopeptides PR Newswire
20.07.22 - PR Newswire
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire
20.07.22 - PR Newswire
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire
17.02.22 - PLX
Oncopeptides Q4 EBIT SEK -389.836 Million
(PLX AI) – Oncopeptides Q4 revenue SEK -21.71 million.
21.01.22 - PR Newswire
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time PR Newswire
05.01.22 - PLX
Oncopeptides Year-End Cash SEK 360 Million After Cutting Costs
(PLX AI) – Oncopeptides cash position at year-end 2021 was approximately SEK 360 million. • Cash burn reduced to SEK 12-15 million monthly for 2022 from SEK 130 million monthly ...
24.11.21 - PLX
Oncopeptides Q3 EBIT SEK -338.913 Million
(PLX AI) – Oncopeptides Q3 revenue SEK 54.276 million.
15.11.21 - PLX
Oncopeptides Says Jakob Lindberg Returns to CEO Role
(PLX AI) – Oncopeptides says Jakob Lindberg appointed CEO. • Previously he was Chief Scientific Officer, and was CEO from 2011 to 2020 • Jakob Lindberg replaces Marty J Duvall, ...
04.11.21 - PLX
Oncopeptides Reduces Clinical Development Program with Melflufen
(PLX AI) – Oncopeptides focuses clinical development efforts to increase cash runway • Oncopeptides reduces the activity level in the clinical development program with melflufen
22.10.21 - PLX
Oncopeptides Withdraws Pepaxto in US After FDA Opinion; Shares Crash 43%
(PLX AI) – Oncopeptides withdraws Pepaxto in US; to scale down organization and focus on R&D. • Oncopeptides says U.S. FDA does not consider that the phase 3 OCEAN study ...
11.09.21 - PR Newswire
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire
11.09.21 - PR Newswire
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire
08.07.21 - PR Newswire
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS - Overall Survival data lead to partial clinical hold
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS - Overall Survival data lead to partial clinical hold PR Newswire
08.07.21 - PR Newswire
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS - Overall Survival data lead to partial clinical hold
Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS - Overall Survival data lead to partial clinical hold PR Newswire
30.06.21 - PR Newswire
Number of shares and votes in Oncopeptides
Number of shares and votes in Oncopeptides PR Newswire
30.06.21 - PR Newswire
Number of shares and votes in Oncopeptides
Number of shares and votes in Oncopeptides PR Newswire
26.05.21 - PR Newswire
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
Bulletin from the Annual General Meeting in Oncopeptides AB (publ) PR Newswire
26.05.21 - PR Newswire
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
Bulletin from the Annual General Meeting in Oncopeptides AB (publ) PR Newswire
26.05.21 - PR Newswire
Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021
Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021 PR Newswire

Newssuche

Videos

newspaper
10.12.24 -10,01%
Technical Trading: Bitcoin Short Chance, weil
Bitcoin Short Typ: Turbo Open End WKN: VC7P6B Hebel: 2,20 Laufzeit: OpenEnd Einstieg: Market ... Mehr »